Vaccination Report – 18 May 2021

1. Vaccine Implementation

• WHO COVAX List (Last Updated 7 May 2021)

Vaccine	Manufacturer	Vaccine type	
BNT162b2	Pfizer-BioNTech (US)	mRNA	
ChAdOx1 (AZS1222)	AstraZeneca/ Oxford (UK)	Non ReplicatingViral vector	
Covishield	Serum Institute of India(India)	Non Replicating Viral Vector	
Ad26.CoV2.S	Johnson & Johnson (US)	Non ReplicatingViral vector	
mRNA-1273	Moderna (US)	mRNA	
BBIBP-CorV	Sinopharm Beijing (China)	Inactivated virus(Vero Cells)	

• 15 Vaccines Approved by at Least One Country

Vaccine Type	mRNA	Non Replicating Viral vector	Inactivated virus	Protein Subunit	Total
In Use	2	5	6	2	15

Source: <u>https://covid19.trackvaccines.org/vaccines/</u> (Last Updated 15 May 2021)

• Vaccination against COVID-19 has now started in **206** locations


(Source: Our World in Data.Last Updated 17 May, 2021)

Location	Doses given	Fully vaccinated (% of population)	At least 1 dose (% of population)
Worldwide	1.5B ^a	359,223,066 ^b	711,137,714°
		(4.6%)	(9.1%)

a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.

b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose). Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.


c: It only has full vaccination totals in some locations.



Source: Official data collated by Our World in Data - Last updated 17 May, 20:20 (London time) Our WorldInData.org/covid-vaccinations • CC BY

Share of people vaccinated against COVID-19, May 17, 2021

This data is only available for countries which report the breakdown of doses administered by first and second doses.



Share of people fully vaccinated against COVID-19 Share of people only partly vaccinated against COVID-19

Source: Official data collated by Our World in Data

2. Relevant Articles

- <u>Guidelines for Reopening a Nation in a SARS-CoV-2 Pandemic: A Path Forward</u>
- Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of <u>Reinfection</u>
- Disease surveillance for the COVID-19 era: time for bold changes